Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2 Despite available first-line treatments, 50% of ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could offer ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by ...

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...

After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...